Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

计划入组 121 人 · 首次发布于 2020 年 12 月 7 日

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

计划入组 130 人 · 首次发布于 2016 年 7 月 7 日

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

计划入组 70 人 · 首次发布于 2022 年 3 月 15 日

Rob-895

ONC-895

MX-895

West University of Timisoara

Romania

Corline Biomedical AB

Sweden

UMass Chan Medical School

United States

Avapritinib Shows Durable Long-Term Response in Indolent Systemic Mastocytosis as Pipeline Expands

Empyrean Therapeutics Acquires TLR-2 Antagonist EMS-312 from Eos Therapies to Advance Cancer Treatment

Merck Animal Health Commits $895 Million to Expand Kansas Manufacturing and R&D Facilities